|本期目录/Table of Contents|

[1]曹桂花,王 伟,毛永敏.对氧磷酶1基因Gln/Arg192多态性与氯吡格雷抵抗相关性初步研究[J].天津医科大学学报,2014,20(01):18-020.
　CAO Gui-hua,WANG Wei,MAO Yong-min.Studies on the correlation between Paraoxonase-1 gene Gln/Arg192 polymorphism and clopidogrel resistance[J].Journal of Tianjin Medical University,2014,20(01):18-020.
点击复制

对氧磷酶1基因Gln/Arg192多态性与氯吡格雷抵抗相关性初步研究(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
20卷
期数:
2014年01期
页码:
18-020
栏目:
临床医学
出版日期:
2014-01-20

文章信息/Info

Title:
Studies on the correlation between Paraoxonase-1 gene Gln/Arg192 polymorphism and clopidogrel resistance
文章编号:
1006-8147(2014)01-0018-03
作者:
曹桂花1; 王 伟2 ; 毛永敏3
（1.天津医科大学研究生院，天津300070；2.天津市胸科医院心内科，天津300050；3. 天津市胸科医院心血管病研究所，天津300051）
Author(s):
CAO Gui-hua1;  WANG Wei2;  MAO Yong-min3
(1.Graduate School ,Tianjin Medical University, Tianjin 300070,China; 2.Department of Cardiology,Chest Hospital of Tianjin, Tianjin 300050,China;3. Cardiovascular Disease Institute of Tianjin Chest Hospital,Tianjin 300051,China)
关键词:
氯吡格雷抵抗; 对氧磷酶1; Gln/Arg192; 基因多态性
Keywords:
clopidogrel resistance;  paraoxonase-1;  Gln/Arg192; gene polymorphism
分类号:
R541.4
DOI:
-
文献标志码:
A
摘要:
  目的：探索对氧磷酶1（PON-1）基因Gln/Arg192多态性与氯吡格雷抵抗（CR）发生的相关性。方法：采用病例-对照研究的方法，共入选260例接受冠状动脉支架安置（PCI）术并服用氯吡格雷抗血小板治疗的冠心病人作为研究对象，检测二磷酸腺苷(ADP)诱导的最大血小板聚集率，服用300 mg氯吡格雷24 h后最大血小板聚集较基线值下降<10%定义为氯吡格雷抵抗（CR）。根据血小板聚集率检测结果将入选人群分为CR组（n= 54）和非氯吡格雷抵抗（NCR）组（n=206）。采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法测定PON-1基因Gln/Arg192基因多态性，分析PON-1基因Gln/Arg192多态性与CR发生的相关性。结果：氯吡格雷抵抗发生率为 20.8%。PON-1基因Gln/Arg192基因型分布频率符合Hardy-Weinberg平衡定律。RR、QR、QQ基因型频率在CR组为38.9%、50.0%、11.1%，而在NCR组为30.6%、57.3%、12.1%，基因型频率分布差异在两组间无统计学意义（P> 0.05）；R 、Q等位基因频率在两组间分别为：69.4%、65.3%和30.6%、34.7%，等位基因频率分布差异在两组间亦无统计学意义（P> 0.05）。结论 ：PON-1基因Gln/Arg192多态性与CR的发生无相关性。
Abstract:
Objective: To investigate the correlation between PON-1 (Paraoxonase-1) gene Gln/Arg192 polymorphism to the occurrence and clopidogrel resistance (CR). Methods: A case-control method was employed in our study. A total of 260 cases of thoracic receiving clopidogrel antithrombotic treatment from coronary heart disease (CHD) from TianJin hospital for PCI were enrolled., the difference between baseline and maximum platelet aggregation（加上below 10%） after the use of clopidogrel 300 mg after 24 h was defined as CR. Accordingly, all the enrolled 260 patients were then divided into CR group (n=54 and non-CR (NCR) group (n=206). Polymerase chain reaction - restriction fragment length polymorphism（PCR-RFLP） was executed to determine the genotypes and the allele frequencies of PON-1 gene Gln/Arg192. Results: The incidence of clopidogrel resistance was 20.8%. The genotype frequencies in Gln/Arg192 of PON-1 gene conformed well to the Hardy-Weinberg equilibrium in both CR group and NCR group. Three frequencies of genotype RR, QR and QQ were 38.9%, 50.0% and 11.1% in CR group, and 30.6%, 57.3% and 12.1%in NCR groups, respectively. No significant difference in genotype and allele frequency was found between CR group and NCR group (P= 0.507 and P=0.208, respectively). Conclusion: Our research shows no correlation exists between PON-1 gene Gln/Arg192 polymorphism and clopidogrel resistance in patients with coronary heart disease.

参考文献/References:

 [1]Tantry U S,Bliden K P,Guibel P A.Resistance to antipatelet drugs：current status and future research[J].Expert Opin Pharmacother，2005，6(12):2027

[2] Sebatine M S, Cannon C P, Gibson C M, et a1.Addition of clopidogrel to aspirin and flbrinolytic therapy formyocardial infarctionwith ST-segmentelevation[J].N Engl J Med, 2005, 352(12): 1179

[3] Sugunataj M S, Palaniswamy C, Selvaraj D R, et al.Clopidogrel resistance[J].Am J Ther, 2010,17(2):210

[4] Bouman H J, Schomig E, Werkum J W van, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy[ J]. Nat Med, 2011,17(1): 110

[5] Massberg S,Svchulz C,Gawaz M.Role of paltelets in the pathophysiology of acute coronary syndrome[ J].Semin Vase Med,2003,3(2):147

[6]伍前发, 张宜青, 林青. 冠状动脉介入治疗后血管再狭窄的药物防治进展[ J]. 武警医学院学报, 2010, 19(9): 753

[7]张晶,马依彤,穆巴拉克. 氯吡格雷抵抗基因多态性的研究进展[ J]. 心血管病学进展, 2012, 33(1): 51

[8]Guthikonda S,lev E I,Kleiman N S. Resistance to antiplatelet therapy[J].Curr Cardiol Rep,2005,7(4):242

[9]Nguyen T A,Diodati J G,Pharand C.Resistance to clopidogrel: a review of the evidence [J].J Am Coll Cardiol,2005,45(8):1157

[10]Osmancik P,Paulu P,Tousek P,et al.High leukocyte count and interleukin 10 predit high on-treatment-platelet-reactivity in patients treated with clopidogrel[J].J Thromb Thrombolysis，2012，33(4):349

[11] Simon T, Verstuyft C, Mary-Krause M, et al.Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4):363

[12] Mega J L, Close S L, Wiviott S D, et al.Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl JMed, 2009, 360(4): 354

[13]唐晓芳，袁晋青.氯吡格雷抵抗基因多态性的研究现状[ J].心血管病学进展,2012,31（2）：165

[14] Richter R J, Jarvik G P, Furlong C E, et al. Paraoxonase 1 status as a risk factor for disease or exposure[ J]. Adv Exp Med Biol, 2010,660: 29

[15] Gupta N, Singh S, Maturu V N, et al. Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis[ J]. PLoS One, 2011, 6(5): e17805

[16]Sibbing D, Koch W, Massberg S, et a1.No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting [ J].Eur Heart J ,2011,32 (13): 1605

相似文献/References:

备注/Memo

备注/Memo:
(作者简介 曹桂花（1988-），女，硕士在读，研究方向：冠心病药物治疗； 通信作者：王伟，E-mail：greatwhlm@yahoo.com。
更新日期/Last Update: 2014-03-25